<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.2.269">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">

<meta name="author" content="Steven M. Smith, PharmD, MPH">
<meta name="author" content="Almut G. Winterstein, PhD">
<meta name="author" content="Matthew J. Gurka, PhD">
<meta name="author" content="Marta G. Walsh, MS">
<meta name="author" content="Shailina Keshwani, MS">
<meta name="author" content="Anne Libby, PhD">
<meta name="author" content="William Hogan, MD, MS">
<meta name="author" content="Carl J. Pepine, MD">
<meta name="author" content="Rhonda M. Cooper-DeHoff, PharmD, MS">

<title>CV med Lab - Initial Antihypertensive Regimens in Newly Treated Patients: Real World Evidence from the OneFlorida+ Clinical Research Network</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1.6em;
  vertical-align: middle;
}
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>


<script src="../site_libs/quarto-nav/quarto-nav.js"></script>
<script src="../site_libs/quarto-nav/headroom.min.js"></script>
<script src="../site_libs/clipboard/clipboard.min.js"></script>
<script src="../site_libs/quarto-search/autocomplete.umd.js"></script>
<script src="../site_libs/quarto-search/fuse.min.js"></script>
<script src="../site_libs/quarto-search/quarto-search.js"></script>
<meta name="quarto:offset" content="../">
<script src="../site_libs/quarto-html/quarto.js"></script>
<script src="../site_libs/quarto-html/popper.min.js"></script>
<script src="../site_libs/quarto-html/tippy.umd.min.js"></script>
<script src="../site_libs/quarto-html/anchor.min.js"></script>
<link href="../site_libs/quarto-html/tippy.css" rel="stylesheet">
<link href="../site_libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="../site_libs/bootstrap/bootstrap.min.js"></script>
<link href="../site_libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="../site_libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">
<script id="quarto-search-options" type="application/json">{
  "location": "navbar",
  "copy-button": false,
  "collapse-after": 3,
  "panel-placement": "end",
  "type": "overlay",
  "limit": 20,
  "language": {
    "search-no-results-text": "No results",
    "search-matching-documents-text": "matching documents",
    "search-copy-link-title": "Copy link to search",
    "search-hide-matches-text": "Hide additional matches",
    "search-more-match-text": "more match in this document",
    "search-more-matches-text": "more matches in this document",
    "search-clear-button-title": "Clear",
    "search-detached-cancel-button-title": "Cancel",
    "search-submit-button-title": "Submit"
  }
}</script>


</head>

<body class="nav-fixed">


<div id="quarto-search-results"></div>
  <header id="quarto-header" class="headroom fixed-top">
    <nav class="navbar navbar-expand-lg navbar-dark ">
      <div class="navbar-container container-fluid">
      <div class="navbar-brand-container">
    <a class="navbar-brand" href="../index.html">
    <span class="navbar-title">{CVmedLab}</span>
    </a>
  </div>
          <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbarCollapse" aria-controls="navbarCollapse" aria-expanded="false" aria-label="Toggle navigation" onclick="if (window.quartoToggleHeadroom) { window.quartoToggleHeadroom(); }">
  <span class="navbar-toggler-icon"></span>
</button>
          <div class="collapse navbar-collapse" id="navbarCollapse">
            <ul class="navbar-nav navbar-nav-scroll me-auto">
  <li class="nav-item">
    <a class="nav-link" href="../about.html">
 <span class="menu-text">about</span></a>
  </li>  
  <li class="nav-item">
    <a class="nav-link" href="../people.html">
 <span class="menu-text">people</span></a>
  </li>  
  <li class="nav-item">
    <a class="nav-link" href="../research.html">
 <span class="menu-text">research</span></a>
  </li>  
  <li class="nav-item">
    <a class="nav-link" href="../papers.html">
 <span class="menu-text">papers</span></a>
  </li>  
  <li class="nav-item">
    <a class="nav-link" href="https://github.com/ssmithm?tab=repositories">
 <span class="menu-text">tools</span></a>
  </li>  
  <li class="nav-item dropdown ">
    <a class="nav-link dropdown-toggle" href="#" id="nav-menu-lab-docs" role="button" data-bs-toggle="dropdown" aria-expanded="false">
 <span class="menu-text">lab docs</span>
    </a>
    <ul class="dropdown-menu" aria-labelledby="nav-menu-lab-docs">    
        <li>
    <a class="dropdown-item" href="../labdocs/table1_gtsummary.html">
 <span class="dropdown-text">Table 1 {R}</span></a>
  </li>  
        <li>
    <a class="dropdown-item" href="../labdocs/cumulative_incidence.html">
 <span class="dropdown-text">Cumulative Incidence Curves {R}</span></a>
  </li>  
        <li>
    <a class="dropdown-item" href="../labdocs/writing.html">
 <span class="dropdown-text">Scientific Writing</span></a>
  </li>  
    </ul>
  </li>
</ul>
            <ul class="navbar-nav navbar-nav-scroll ms-auto">
  <li class="nav-item compact">
    <a class="nav-link" href="https://github.com/cvmedlab"><i class="bi bi-github" role="img">
</i> 
 <span class="menu-text"></span></a>
  </li>  
  <li class="nav-item compact">
    <a class="nav-link" href="https://twitter.com/CVmedLab"><i class="bi bi-twitter" role="img">
</i> 
 <span class="menu-text"></span></a>
  </li>  
</ul>
              <div id="quarto-search" class="" title="Search"></div>
          </div> <!-- /navcollapse -->
      </div> <!-- /container-fluid -->
    </nav>
</header>
<!-- content -->
<div id="quarto-content" class="quarto-container page-columns page-rows-contents page-layout-article page-navbar">
<!-- sidebar -->
<!-- margin-sidebar -->
    <div id="quarto-margin-sidebar" class="sidebar margin-sidebar">
        <nav id="TOC" role="doc-toc" class="toc-active">
    <h2 id="toc-title">Sections</h2>
   
  <ul>
  <li><a href="#introduction" id="toc-introduction" class="nav-link active" data-scroll-target="#introduction">INTRODUCTION</a></li>
  <li><a href="#methods" id="toc-methods" class="nav-link" data-scroll-target="#methods">METHODS</a>
  <ul>
  <li><a href="#data-source" id="toc-data-source" class="nav-link" data-scroll-target="#data-source">Data Source</a></li>
  <li><a href="#participants-and-cohort-development" id="toc-participants-and-cohort-development" class="nav-link" data-scroll-target="#participants-and-cohort-development">Participants and Cohort Development</a></li>
  <li><a href="#data-collection" id="toc-data-collection" class="nav-link" data-scroll-target="#data-collection">Data Collection</a></li>
  <li><a href="#data-analysis" id="toc-data-analysis" class="nav-link" data-scroll-target="#data-analysis">Data Analysis</a></li>
  </ul></li>
  <li><a href="#results" id="toc-results" class="nav-link" data-scroll-target="#results">RESULTS</a>
  <ul>
  <li><a href="#initial-antihypertensive-use" id="toc-initial-antihypertensive-use" class="nav-link" data-scroll-target="#initial-antihypertensive-use">Initial Antihypertensive Use</a></li>
  <li><a href="#time-trends" id="toc-time-trends" class="nav-link" data-scroll-target="#time-trends">Time Trends</a></li>
  <li><a href="#stratified-analyses-demographics-and-comorbidities" id="toc-stratified-analyses-demographics-and-comorbidities" class="nav-link" data-scroll-target="#stratified-analyses-demographics-and-comorbidities">Stratified Analyses: Demographics and Comorbidities</a></li>
  </ul></li>
  <li><a href="#discussion" id="toc-discussion" class="nav-link" data-scroll-target="#discussion">DISCUSSION</a></li>
  <li><a href="#funding" id="toc-funding" class="nav-link" data-scroll-target="#funding">Funding</a></li>
  <li><a href="#disclosures" id="toc-disclosures" class="nav-link" data-scroll-target="#disclosures">Disclosures</a></li>
  <li><a href="#supplement" id="toc-supplement" class="nav-link" data-scroll-target="#supplement">Supplement</a></li>
  </ul>
</nav>
    </div>
<!-- main -->
<main class="content" id="quarto-document-content">

<header id="title-block-header" class="quarto-title-block default">
<div class="quarto-title">
<h1 class="title">Initial Antihypertensive Regimens in Newly Treated Patients: Real World Evidence from the OneFlorida+ Clinical Research Network</h1>
</div>


<div class="quarto-title-meta-author">
  <div class="quarto-title-meta-heading">Authors</div>
  <div class="quarto-title-meta-heading">Affiliations</div>
  
    <div class="quarto-title-meta-contents">
    Steven M. Smith, PharmD, MPH 
  </div>
    <div class="quarto-title-meta-contents">
        <p class="affiliation">
            Department of Pharmaceutical Outcomes &amp; Policy, College of Pharmacy, University of Florida
          </p>
        <p class="affiliation">
            Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida
          </p>
        <p class="affiliation">
            Center for Integrative Cardiovascular and Metabolic Disease, University of Florida
          </p>
      </div>
      <div class="quarto-title-meta-contents">
    Almut G. Winterstein, PhD 
  </div>
    <div class="quarto-title-meta-contents">
        <p class="affiliation">
            Department of Pharmaceutical Outcomes &amp; Policy, College of Pharmacy, University of Florida
          </p>
      </div>
      <div class="quarto-title-meta-contents">
    Matthew J. Gurka, PhD 
  </div>
    <div class="quarto-title-meta-contents">
        <p class="affiliation">
            Department of Pediatrics, College of Medicine, University of Florida
          </p>
      </div>
      <div class="quarto-title-meta-contents">
    Marta G. Walsh, MS 
  </div>
    <div class="quarto-title-meta-contents">
        <p class="affiliation">
            Department of Pharmaceutical Outcomes &amp; Policy, College of Pharmacy, University of Florida
          </p>
      </div>
      <div class="quarto-title-meta-contents">
    Shailina Keshwani, MS 
  </div>
    <div class="quarto-title-meta-contents">
        <p class="affiliation">
            Department of Pharmaceutical Outcomes &amp; Policy, College of Pharmacy, University of Florida
          </p>
      </div>
      <div class="quarto-title-meta-contents">
    Anne Libby, PhD 
  </div>
    <div class="quarto-title-meta-contents">
        <p class="affiliation">
            Department of Emergency Medicine, School of Medicine, University of Colorado Denver
          </p>
      </div>
      <div class="quarto-title-meta-contents">
    William Hogan, MD, MS 
  </div>
    <div class="quarto-title-meta-contents">
        <p class="affiliation">
            Department of Health Outcomes &amp; Biomedical Informatics, College of Medicine, University of Florida
          </p>
      </div>
      <div class="quarto-title-meta-contents">
    Carl J. Pepine, MD 
  </div>
    <div class="quarto-title-meta-contents">
        <p class="affiliation">
            Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida
          </p>
      </div>
      <div class="quarto-title-meta-contents">
    Rhonda M. Cooper-DeHoff, PharmD, MS 
  </div>
    <div class="quarto-title-meta-contents">
        <p class="affiliation">
            Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida
          </p>
        <p class="affiliation">
            Department of Pharmacotherapy &amp; Translational Research, College of Pharmacy, University of Florida
          </p>
      </div>
    </div>

<div class="quarto-title-meta">

      
  
    
  </div>
  

</header>

<p><em>Status: in press (Journal of the American Heart Association)</em></p>
<section id="introduction" class="level3">
<h3 class="anchored" data-anchor-id="introduction">INTRODUCTION</h3>
<p>Hypertension affects an estimated 120 million individuals in the U.S. and is the leading modifiable risk factor for cardiovascular disease and death.<span class="citation" data-cites="muntner_blood_2022"><sup><a href="#ref-muntner_blood_2022" role="doc-biblioref">1</a></sup></span> Nearly all of these individuals ultimately require antihypertensive therapy to achieve blood pressure (BP) control, and as a consequence, several antihypertensive drugs are among the most commonly used medications worldwide. Consensus U.S. and international guidelines have long recommended certain antihypertensive classes as ‘first-line’ therapies – namely angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), thiazide diuretics, calcium channel blockers (CCBs), and, until relatively recently, β-blockers.<span class="citation" data-cites="williams_2018_2018 whelton_2017_2018"><sup><a href="#ref-williams_2018_2018" role="doc-biblioref">2</a>,<a href="#ref-whelton_2017_2018" role="doc-biblioref">3</a></sup></span> However, for most patients with uncomplicated hypertension, guidelines generally do not prioritize any of these classes except in select circumstances, leaving prescribers to choose from some 30 to 40 antihypertensive drugs when initiating antihypertensive therapy.</p>
<p>Real world antihypertensive utilization patterns have been studied extensively, but in almost all cases, the focus of these studies has been on treatment patterns in prevalent hypertension cohorts.<span class="citation" data-cites="hou_frequency_2021 gu_age_2016 gu_patterns_2019 gu_racial_2017 shah_current_2017 zhou_national_2015 koifman_trends_2014 wang_hypertension_2014 weir_how_2011 zheutlin_factors_2022 derington_trends_2020"><sup><a href="#ref-hou_frequency_2021" role="doc-biblioref">4</a>–<a href="#ref-derington_trends_2020" role="doc-biblioref">14</a></sup></span> These studies provide useful insight into overall antihypertensive use in populations. However, they rarely have distinguished between patients who are early in their treatment course from those with long-standing hypertension and who may have extensive treatment histories and multi-drug regimens that have evolved over time. Thus, very little is known about contemporary patterns of early antihypertensive care, including initial antihypertensive regimens, and to what extent these accord with care typically recommended in consensus guidelines. These gaps are noteworthy in light of the fact that only approximately one in five U.S. patients with hypertension have BP controlled to &lt;130/80 mm Hg.<span class="citation" data-cites="muntner_blood_2022"><sup><a href="#ref-muntner_blood_2022" role="doc-biblioref">1</a></sup></span> Thus, delays in achieving BP control are exceedingly common in routine practice and extend high-risk periods, leading to worse outcomes.<span class="citation" data-cites="oconnor_benefits_2013 weir_how_2011"><sup><a href="#ref-weir_how_2011" role="doc-biblioref">12</a>,<a href="#ref-oconnor_benefits_2013" role="doc-biblioref">15</a></sup></span> A greater understanding of how antihypertensive regimens emerge and evolve early in therapy may aid in identifying quality care gaps that can be intervened on.</p>
<p>To address this gap, we used the OneFlorida+ Clinical Research Consortium (hereafter, OneFlorida+) to characterize initial treatment regimens among a diverse cohort of new users of antihypertensive therapy. We were principally interested in the distribution of classes, specific antihypertensive drugs within classes, how these distributions differed in pre-specified demographic and clinical groups, and their trends over time.</p>
</section>
<section id="methods" class="level3">
<h3 class="anchored" data-anchor-id="methods">METHODS</h3>
<p>We conducted a cross-sectional study of initial antihypertensive medication use among individuals with newly-treated hypertension using patient-level data from OneFlorida+ from 2012 through September 2021. The study was approved by the University of Florida Institutional Review Board, with a full waiver of informed consent for research involving data previously collected for non-research purposes. The OneFlorida+ steering committee also approved the study. Data underlying this study may be obtained through the OneFlorida+ Front Door (<a href="https://onefloridaconsortium.org/" class="uri">https://onefloridaconsortium.org/</a>) by qualified researchers trained in human subject confidentiality protocols.</p>
<section id="data-source" class="level4">
<h4 class="anchored" data-anchor-id="data-source">Data Source</h4>
<p>OneFlorida+ is one of eight clinical research networks comprising the Patient-Centered Outcomes Research network (PCORnet). OneFlorida+ serves as a data repository for patient-level data from both health system partners and insurers. Administrative claims data for this project included all available Florida Medicaid (Jan 1, 2012 through Sep 30, 2021) and Medicare (Jan 1, 2012 through Dec 31, 2017) data. All data sources are mapped to the PCORnet common data model (version 6.0) to ensure standardization of data elements across sources. Major data elements in the common data model include demographics, enrollment, encounters, diagnoses, procedures, dispensed medications, and deaths. In the present study, we included only Florida Medicaid or Medicare recipients with claims data available. This approach was chosen to minimize misclassification of new antihypertensive users, by ensuring a sustained period of continuous eligibility (≥1 year) without any dispensing history of antihypertensive therapy prior to the index antihypertensive fill.</p>
</section>
<section id="participants-and-cohort-development" class="level4">
<h4 class="anchored" data-anchor-id="participants-and-cohort-development">Participants and Cohort Development</h4>
<p>The study design and data collection are summarized in <a href="initial_antihypertensive_prescribing_onefl_suppl.pdf" target="_blank">Figure S1</a>. Patients were included if they were aged ≥18 years, dispensed a new antihypertensive medication from ≥1 of 5 ‘first-line’ classes (ACEIs, ARBs, CCBs, thiazide diuretics, or beta blockers) between Dec 31, 2012 and Dec 31, 2017 (for Medicare recipients) or September 30, 2021 (Medicaid recipients), and were continuously enrolled in the respective coverage for 365 days prior to and including the date of first dispensing of the above antihypertensive medication(s). The date of first antihypertensive medication fill was considered the index date, and data for all antihypertensives filled on the index date were collected, even if ≥1 of these newly filled antihypertensives were not ‘first-line’ classes. Patients filling antihypertensives from second line classes prior to the first fill date of the above first-line classes were not considered new-users and were excluded from the cohort. Eligible antihypertensive drugs are summarized in <a href="initial_antihypertensive_prescribing_onefl_suppl.pdf" target="_blank">Table S1</a> and a complete list of national drug codes (NDCs) can be downloaded at <a href="https://github.com/ssmithm/rxnorm-drug-lists/tree/master/antihypertensive_drugs" class="uri">https://github.com/ssmithm/rxnorm-drug-lists/tree/master/antihypertensive_drugs</a>. Patients were also required to have a hypertension diagnosis (ICD-9, 401.X; ICD-10, I10) within the baseline period defined as 365 days prior to and including the index date.</p>
</section>
<section id="data-collection" class="level4">
<h4 class="anchored" data-anchor-id="data-collection">Data Collection</h4>
<p>Baseline characteristics were measured during the baseline period (generally 1 year prior to and including index date), as per the definitions summarized in <a href="initial_antihypertensive_prescribing_onefl_suppl.pdf" target="_blank">Table S2</a>. Demographic information (sex, race, ethnicity, birth date) was drawn from the original claims data demographic files (mapped to the PCORnet common data model); when possible, we supplemented missing values with linked EHR-based data for sex, race, and ethnicity (each patient-reported). Discrepancies between claims and EHR-based demographic data were resolved by giving self-report EHR data primacy. Antihypertensive regimen information was collected for all antihypertensives dispensed on the index date, with antihypertensives grouped into classes as summarized in <a href="initial_antihypertensive_prescribing_onefl_suppl.pdf" target="_blank">Table S1</a>.</p>
</section>
<section id="data-analysis" class="level4">
<h4 class="anchored" data-anchor-id="data-analysis">Data Analysis</h4>
<p>We summarized baseline characteristics using mean and standard deviation for continuous variables and n (%) for categorical variables in the overall study population and stratified by insurer (Medicaid, Medicare). Within insurance strata, we calculated the proportion of individuals initiating each class and, within class, each drug. In addition to stratifying analyses by insurer, we performed stratified analyses by pre-specified demographic (sex, race, ethnicity) and comorbidity (chronic kidney disease [CKD], diabetes, and clinical atherosclerotic cardiovascular disease [ASCVD]) strata and assessed differences by calculating standardized mean differences (SMD) between groups.<span class="citation" data-cites="austin_using_2009"><sup><a href="#ref-austin_using_2009" role="doc-biblioref">16</a></sup></span> We further assessed use of recommended therapy among Black/African American patients with and without CKD or heart failure (HF), based on explicit recommendations in the current U.S. guidelines (i.e., DHP CCBs or thiazides as preferred initial agents among those without CKD or HF).<span class="citation" data-cites="whelton_2017_2018 noauthor_2014_nodate"><sup><a href="#ref-whelton_2017_2018" role="doc-biblioref">3</a>,<a href="#ref-noauthor_2014_nodate" role="doc-biblioref">17</a></sup></span> For patients initiating dual antihypertensive regimens, we calculated the proportion of regimens that were guideline concordant (two first-line antihypertensives from different classes), partially concordant (one first-line and one second-line) or discordant (two second-line agents or two first-line agents from the same class) according to current U.S. guidelines.<span class="citation" data-cites="whelton_2017_2018"><sup><a href="#ref-whelton_2017_2018" role="doc-biblioref">3</a></sup></span> Finally, we analyzed changes over time in initial antihypertensive regimens by stratifying medication use according to the year of the index date and graphically displaying these data to identify trends in proportion of each class prescribed. The Cochrane-Armitage test was used for trend tests of antihypertensive classes. All data were analyzed with R 4.2.0 (R Foundation, Vienna, Austria).</p>
</section>
</section>
<section id="results" class="level3">
<h3 class="anchored" data-anchor-id="results">RESULTS</h3>
<p>We identified a total of 143,054 patients with newly-treated hypertension, with approximately similar numbers of Medicaid (n=71,774; 50.1% of total cohort) and Medicare (n=71,280; 49.8% of total cohort) recipients (<a href="initial_antihypertensive_prescribing_onefl_suppl.pdf" target="_blank">Figure S2</a>). Baseline characteristics of the cohort are summarized in <a href="#tbl-1">Table&nbsp;1</a>. Briefly, patients were aged 59 years on average (Medicaid, 47 years vs.&nbsp;Medicare, 72 years) and 57% were women. A plurality of patients self-reported as White (49% overall; Medicaid, 35% vs.&nbsp;Medicare, 63%), 24% (Medicaid, 31%; Medicare, 17%) as Black or African American, and 12% had missing race information; 16% (Medicaid, 18%; Medicare, 14%) were Hispanic. The most common comorbidities were diabetes (21%) and depression (18%), and nearly one-quarter were current smokers. Chronic kidney disease and ASCVD were considerably more common in the Medicare versus Medicaid population.</p>
<div class="cell">
<div class="cell-output-display">
<div id="tbl-1" class="anchored">

<div id="lemijcerii" style="padding-left:0px;padding-right:0px;padding-top:10px;padding-bottom:10px;overflow-x:auto;overflow-y:auto;width:auto;height:auto;">
<style>html {
  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;
}

:where(#lemijcerii) .gt_table {
  display: table;
  border-collapse: collapse;
  margin-left: auto;
  margin-right: auto;
  color: #333333;
  font-size: 16px;
  font-weight: normal;
  font-style: normal;
  background-color: #FFFFFF;
  width: auto;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #A8A8A8;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #A8A8A8;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
}

:where(#lemijcerii) .gt_heading {
  background-color: #FFFFFF;
  text-align: center;
  border-bottom-color: #FFFFFF;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

:where(#lemijcerii) .gt_caption {
  padding-top: 4px;
  padding-bottom: 4px;
}

:where(#lemijcerii) .gt_title {
  color: #333333;
  font-size: 125%;
  font-weight: initial;
  padding-top: 4px;
  padding-bottom: 4px;
  padding-left: 5px;
  padding-right: 5px;
  border-bottom-color: #FFFFFF;
  border-bottom-width: 0;
}

:where(#lemijcerii) .gt_subtitle {
  color: #333333;
  font-size: 85%;
  font-weight: initial;
  padding-top: 0;
  padding-bottom: 6px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-color: #FFFFFF;
  border-top-width: 0;
}

:where(#lemijcerii) .gt_bottom_border {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

:where(#lemijcerii) .gt_col_headings {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

:where(#lemijcerii) .gt_col_heading {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 6px;
  padding-left: 5px;
  padding-right: 5px;
  overflow-x: hidden;
}

:where(#lemijcerii) .gt_column_spanner_outer {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  padding-top: 0;
  padding-bottom: 0;
  padding-left: 4px;
  padding-right: 4px;
}

:where(#lemijcerii) .gt_column_spanner_outer:first-child {
  padding-left: 0;
}

:where(#lemijcerii) .gt_column_spanner_outer:last-child {
  padding-right: 0;
}

:where(#lemijcerii) .gt_column_spanner {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 5px;
  overflow-x: hidden;
  display: inline-block;
  width: 100%;
}

:where(#lemijcerii) .gt_group_heading {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  text-align: left;
}

:where(#lemijcerii) .gt_empty_group_heading {
  padding: 0.5px;
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: middle;
}

:where(#lemijcerii) .gt_from_md > :first-child {
  margin-top: 0;
}

:where(#lemijcerii) .gt_from_md > :last-child {
  margin-bottom: 0;
}

:where(#lemijcerii) .gt_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  margin: 10px;
  border-top-style: solid;
  border-top-width: 1px;
  border-top-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  overflow-x: hidden;
}

:where(#lemijcerii) .gt_stub {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 5px;
  padding-right: 5px;
}

:where(#lemijcerii) .gt_stub_row_group {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 5px;
  padding-right: 5px;
  vertical-align: top;
}

:where(#lemijcerii) .gt_row_group_first td {
  border-top-width: 2px;
}

:where(#lemijcerii) .gt_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

:where(#lemijcerii) .gt_first_summary_row {
  border-top-style: solid;
  border-top-color: #D3D3D3;
}

:where(#lemijcerii) .gt_first_summary_row.thick {
  border-top-width: 2px;
}

:where(#lemijcerii) .gt_last_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

:where(#lemijcerii) .gt_grand_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

:where(#lemijcerii) .gt_first_grand_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: double;
  border-top-width: 6px;
  border-top-color: #D3D3D3;
}

:where(#lemijcerii) .gt_striped {
  background-color: rgba(128, 128, 128, 0.05);
}

:where(#lemijcerii) .gt_table_body {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

:where(#lemijcerii) .gt_footnotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

:where(#lemijcerii) .gt_footnote {
  margin: 0px;
  font-size: 90%;
  padding-left: 4px;
  padding-right: 4px;
  padding-left: 5px;
  padding-right: 5px;
}

:where(#lemijcerii) .gt_sourcenotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

:where(#lemijcerii) .gt_sourcenote {
  font-size: 90%;
  padding-top: 4px;
  padding-bottom: 4px;
  padding-left: 5px;
  padding-right: 5px;
}

:where(#lemijcerii) .gt_left {
  text-align: left;
}

:where(#lemijcerii) .gt_center {
  text-align: center;
}

:where(#lemijcerii) .gt_right {
  text-align: right;
  font-variant-numeric: tabular-nums;
}

:where(#lemijcerii) .gt_font_normal {
  font-weight: normal;
}

:where(#lemijcerii) .gt_font_bold {
  font-weight: bold;
}

:where(#lemijcerii) .gt_font_italic {
  font-style: italic;
}

:where(#lemijcerii) .gt_super {
  font-size: 65%;
}

:where(#lemijcerii) .gt_footnote_marks {
  font-style: italic;
  font-weight: normal;
  font-size: 75%;
  vertical-align: 0.4em;
}

:where(#lemijcerii) .gt_asterisk {
  font-size: 100%;
  vertical-align: 0;
}

:where(#lemijcerii) .gt_indent_1 {
  text-indent: 5px;
}

:where(#lemijcerii) .gt_indent_2 {
  text-indent: 10px;
}

:where(#lemijcerii) .gt_indent_3 {
  text-indent: 15px;
}

:where(#lemijcerii) .gt_indent_4 {
  text-indent: 20px;
}

:where(#lemijcerii) .gt_indent_5 {
  text-indent: 25px;
}
</style>
<table class="gt_table"><caption>Table&nbsp;1:  Baseline characteristics of new antihypertensive users. </caption>
  
  <thead class="gt_col_headings">
    <tr>
      <th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="1" colspan="1" scope="col" id="<strong>Characteristic</strong>"><strong>Characteristic</strong></th>
      <th class="gt_col_heading gt_columns_bottom_border gt_center" rowspan="1" colspan="1" scope="col" id="<strong>Overall</strong>, N = 143,054<sup class=&quot;gt_footnote_marks&quot;>1</sup>"><strong>Overall</strong>, N = 143,054<sup class="gt_footnote_marks">1</sup></th>
      <th class="gt_col_heading gt_columns_bottom_border gt_center" rowspan="1" colspan="1" scope="col" id="<strong>Medicaid</strong>, N = 71,774<sup class=&quot;gt_footnote_marks&quot;>1</sup>"><strong>Medicaid</strong>, N = 71,774<sup class="gt_footnote_marks">1</sup></th>
      <th class="gt_col_heading gt_columns_bottom_border gt_center" rowspan="1" colspan="1" scope="col" id="<strong>Medicare</strong>, N = 71,280<sup class=&quot;gt_footnote_marks&quot;>1</sup>"><strong>Medicare</strong>, N = 71,280<sup class="gt_footnote_marks">1</sup></th>
    </tr>
  </thead>
  <tbody class="gt_table_body">
    <tr><td headers="label" class="gt_row gt_left">Age, years</td>
<td headers="stat_0" class="gt_row gt_center">59 ± 22</td>
<td headers="stat_1" class="gt_row gt_center">47 ± 14</td>
<td headers="stat_2" class="gt_row gt_center">72 ± 20</td></tr>
    <tr><td headers="label" class="gt_row gt_left">Age Category</td>
<td headers="stat_0" class="gt_row gt_center"></td>
<td headers="stat_1" class="gt_row gt_center"></td>
<td headers="stat_2" class="gt_row gt_center"></td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;&lt;45 y</td>
<td headers="stat_0" class="gt_row gt_center">38,213 (27%)</td>
<td headers="stat_1" class="gt_row gt_center">33,176 (46%)</td>
<td headers="stat_2" class="gt_row gt_center">5,037 (7.1%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;45-64 y</td>
<td headers="stat_0" class="gt_row gt_center">51,007 (36%)</td>
<td headers="stat_1" class="gt_row gt_center">34,274 (48%)</td>
<td headers="stat_2" class="gt_row gt_center">16,733 (23%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;&gt;65 y</td>
<td headers="stat_0" class="gt_row gt_center">53,834 (38%)</td>
<td headers="stat_1" class="gt_row gt_center">4,324 (6.0%)</td>
<td headers="stat_2" class="gt_row gt_center">49,510 (69%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">Sex</td>
<td headers="stat_0" class="gt_row gt_center"></td>
<td headers="stat_1" class="gt_row gt_center"></td>
<td headers="stat_2" class="gt_row gt_center"></td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;Female</td>
<td headers="stat_0" class="gt_row gt_center">81,555 (57%)</td>
<td headers="stat_1" class="gt_row gt_center">43,011 (60%)</td>
<td headers="stat_2" class="gt_row gt_center">38,544 (54%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;Male</td>
<td headers="stat_0" class="gt_row gt_center">61,493 (43%)</td>
<td headers="stat_1" class="gt_row gt_center">28,760 (40%)</td>
<td headers="stat_2" class="gt_row gt_center">32,733 (46%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;Unknown</td>
<td headers="stat_0" class="gt_row gt_center">6 (&lt;0.1%)</td>
<td headers="stat_1" class="gt_row gt_center">3 (&lt;0.1%)</td>
<td headers="stat_2" class="gt_row gt_center">3 (&lt;0.1%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">Race</td>
<td headers="stat_0" class="gt_row gt_center"></td>
<td headers="stat_1" class="gt_row gt_center"></td>
<td headers="stat_2" class="gt_row gt_center"></td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;American Indian or Alaska Native</td>
<td headers="stat_0" class="gt_row gt_center">334 (0.2%)</td>
<td headers="stat_1" class="gt_row gt_center">165 (0.2%)</td>
<td headers="stat_2" class="gt_row gt_center">169 (0.2%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;Asian</td>
<td headers="stat_0" class="gt_row gt_center">1,447 (1.0%)</td>
<td headers="stat_1" class="gt_row gt_center">659 (0.9%)</td>
<td headers="stat_2" class="gt_row gt_center">788 (1.1%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;Black or African American</td>
<td headers="stat_0" class="gt_row gt_center">33,814 (24%)</td>
<td headers="stat_1" class="gt_row gt_center">22,041 (31%)</td>
<td headers="stat_2" class="gt_row gt_center">11,773 (17%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;Native Hawaiian or Other Pacific</td>
<td headers="stat_0" class="gt_row gt_center">33 (&lt;0.1%)</td>
<td headers="stat_1" class="gt_row gt_center">11 (&lt;0.1%)</td>
<td headers="stat_2" class="gt_row gt_center">22 (&lt;0.1%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;White</td>
<td headers="stat_0" class="gt_row gt_center">70,156 (49%)</td>
<td headers="stat_1" class="gt_row gt_center">25,304 (35%)</td>
<td headers="stat_2" class="gt_row gt_center">44,852 (63%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;Multiple Race</td>
<td headers="stat_0" class="gt_row gt_center">503 (0.4%)</td>
<td headers="stat_1" class="gt_row gt_center">167 (0.2%)</td>
<td headers="stat_2" class="gt_row gt_center">336 (0.5%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;Other</td>
<td headers="stat_0" class="gt_row gt_center">20,555 (14%)</td>
<td headers="stat_1" class="gt_row gt_center">11,610 (16%)</td>
<td headers="stat_2" class="gt_row gt_center">8,945 (13%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;Unknown</td>
<td headers="stat_0" class="gt_row gt_center">16,212 (11%)</td>
<td headers="stat_1" class="gt_row gt_center">11,817 (16%)</td>
<td headers="stat_2" class="gt_row gt_center">4,395 (6.2%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">Ethnicity</td>
<td headers="stat_0" class="gt_row gt_center"></td>
<td headers="stat_1" class="gt_row gt_center"></td>
<td headers="stat_2" class="gt_row gt_center"></td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;Hispanic</td>
<td headers="stat_0" class="gt_row gt_center">22,680 (16%)</td>
<td headers="stat_1" class="gt_row gt_center">13,016 (18%)</td>
<td headers="stat_2" class="gt_row gt_center">9,664 (14%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;Not Hispanic</td>
<td headers="stat_0" class="gt_row gt_center">99,483 (70%)</td>
<td headers="stat_1" class="gt_row gt_center">44,696 (62%)</td>
<td headers="stat_2" class="gt_row gt_center">54,787 (77%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;Unknown</td>
<td headers="stat_0" class="gt_row gt_center">20,891 (15%)</td>
<td headers="stat_1" class="gt_row gt_center">14,062 (20%)</td>
<td headers="stat_2" class="gt_row gt_center">6,829 (9.6%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">Current Smoker</td>
<td headers="stat_0" class="gt_row gt_center">32,080 (22%)</td>
<td headers="stat_1" class="gt_row gt_center">17,035 (24%)</td>
<td headers="stat_2" class="gt_row gt_center">15,045 (21%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">Diabetes</td>
<td headers="stat_0" class="gt_row gt_center">29,633 (21%)</td>
<td headers="stat_1" class="gt_row gt_center">13,802 (19%)</td>
<td headers="stat_2" class="gt_row gt_center">15,831 (22%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">Chronic kidney disease</td>
<td headers="stat_0" class="gt_row gt_center">17,626 (12%)</td>
<td headers="stat_1" class="gt_row gt_center">5,111 (7.1%)</td>
<td headers="stat_2" class="gt_row gt_center">12,515 (18%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">End-stage renal disease</td>
<td headers="stat_0" class="gt_row gt_center">1,072 (0.7%)</td>
<td headers="stat_1" class="gt_row gt_center">233 (0.3%)</td>
<td headers="stat_2" class="gt_row gt_center">839 (1.2%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">Heart failure w/ reduced EF</td>
<td headers="stat_0" class="gt_row gt_center">2,858 (2.0%)</td>
<td headers="stat_1" class="gt_row gt_center">1,264 (1.8%)</td>
<td headers="stat_2" class="gt_row gt_center">1,594 (2.2%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">Coronary heart disease</td>
<td headers="stat_0" class="gt_row gt_center">7,940 (5.6%)</td>
<td headers="stat_1" class="gt_row gt_center">2,742 (3.8%)</td>
<td headers="stat_2" class="gt_row gt_center">5,198 (7.3%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">Prior coronary revascularization</td>
<td headers="stat_0" class="gt_row gt_center">728 (0.5%)</td>
<td headers="stat_1" class="gt_row gt_center">142 (0.2%)</td>
<td headers="stat_2" class="gt_row gt_center">586 (0.8%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">Prior stroke or TIA</td>
<td headers="stat_0" class="gt_row gt_center">2,292 (1.6%)</td>
<td headers="stat_1" class="gt_row gt_center">309 (0.4%)</td>
<td headers="stat_2" class="gt_row gt_center">1,983 (2.8%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">Peripheral arterial disease</td>
<td headers="stat_0" class="gt_row gt_center">9,388 (6.6%)</td>
<td headers="stat_1" class="gt_row gt_center">1,483 (2.1%)</td>
<td headers="stat_2" class="gt_row gt_center">7,905 (11%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">History of clinical ASCVD</td>
<td headers="stat_0" class="gt_row gt_center">17,416 (12%)</td>
<td headers="stat_1" class="gt_row gt_center">4,229 (5.9%)</td>
<td headers="stat_2" class="gt_row gt_center">13,187 (19%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">Atrial fibrillation</td>
<td headers="stat_0" class="gt_row gt_center">10,024 (7.0%)</td>
<td headers="stat_1" class="gt_row gt_center">1,375 (1.9%)</td>
<td headers="stat_2" class="gt_row gt_center">8,649 (12%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">Chronic obstructive pulmonary disease</td>
<td headers="stat_0" class="gt_row gt_center">7,769 (5.4%)</td>
<td headers="stat_1" class="gt_row gt_center">4,588 (6.4%)</td>
<td headers="stat_2" class="gt_row gt_center">3,181 (4.5%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">Asthma</td>
<td headers="stat_0" class="gt_row gt_center">6,066 (4.2%)</td>
<td headers="stat_1" class="gt_row gt_center">4,855 (6.8%)</td>
<td headers="stat_2" class="gt_row gt_center">1,211 (1.7%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">Depression</td>
<td headers="stat_0" class="gt_row gt_center">25,690 (18%)</td>
<td headers="stat_1" class="gt_row gt_center">10,670 (15%)</td>
<td headers="stat_2" class="gt_row gt_center">15,020 (21%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">Combined Comorbidity Score</td>
<td headers="stat_0" class="gt_row gt_center">2.5 ± 3.5</td>
<td headers="stat_1" class="gt_row gt_center">1.6 ± 2.8</td>
<td headers="stat_2" class="gt_row gt_center">3.5 ± 3.9</td></tr>
    <tr><td headers="label" class="gt_row gt_left">Statin</td>
<td headers="stat_0" class="gt_row gt_center">31,421 (22%)</td>
<td headers="stat_1" class="gt_row gt_center">13,201 (18%)</td>
<td headers="stat_2" class="gt_row gt_center">18,220 (26%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">Aspirin</td>
<td headers="stat_0" class="gt_row gt_center">11,663 (8.2%)</td>
<td headers="stat_1" class="gt_row gt_center">6,115 (8.5%)</td>
<td headers="stat_2" class="gt_row gt_center">5,548 (7.8%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">Index Year</td>
<td headers="stat_0" class="gt_row gt_center"></td>
<td headers="stat_1" class="gt_row gt_center"></td>
<td headers="stat_2" class="gt_row gt_center"></td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;2012</td>
<td headers="stat_0" class="gt_row gt_center">32 (&lt;0.1%)</td>
<td headers="stat_1" class="gt_row gt_center">1 (&lt;0.1%)</td>
<td headers="stat_2" class="gt_row gt_center">31 (&lt;0.1%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;2013</td>
<td headers="stat_0" class="gt_row gt_center">17,728 (12%)</td>
<td headers="stat_1" class="gt_row gt_center">485 (0.7%)</td>
<td headers="stat_2" class="gt_row gt_center">17,243 (24%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;2014</td>
<td headers="stat_0" class="gt_row gt_center">31,711 (22%)</td>
<td headers="stat_1" class="gt_row gt_center">11,457 (16%)</td>
<td headers="stat_2" class="gt_row gt_center">20,254 (28%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;2015</td>
<td headers="stat_0" class="gt_row gt_center">27,205 (19%)</td>
<td headers="stat_1" class="gt_row gt_center">11,039 (15%)</td>
<td headers="stat_2" class="gt_row gt_center">16,166 (23%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;2016</td>
<td headers="stat_0" class="gt_row gt_center">19,283 (13%)</td>
<td headers="stat_1" class="gt_row gt_center">10,664 (15%)</td>
<td headers="stat_2" class="gt_row gt_center">8,619 (12%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;2017</td>
<td headers="stat_0" class="gt_row gt_center">18,661 (13%)</td>
<td headers="stat_1" class="gt_row gt_center">9,694 (14%)</td>
<td headers="stat_2" class="gt_row gt_center">8,967 (13%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;2018</td>
<td headers="stat_0" class="gt_row gt_center">8,963 (6.3%)</td>
<td headers="stat_1" class="gt_row gt_center">8,963 (12%)</td>
<td headers="stat_2" class="gt_row gt_center">0 (0%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;2019</td>
<td headers="stat_0" class="gt_row gt_center">8,164 (5.7%)</td>
<td headers="stat_1" class="gt_row gt_center">8,164 (11%)</td>
<td headers="stat_2" class="gt_row gt_center">0 (0%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;2020</td>
<td headers="stat_0" class="gt_row gt_center">7,520 (5.3%)</td>
<td headers="stat_1" class="gt_row gt_center">7,520 (10%)</td>
<td headers="stat_2" class="gt_row gt_center">0 (0%)</td></tr>
    <tr><td headers="label" class="gt_row gt_left">&nbsp;&nbsp;&nbsp;&nbsp;2021</td>
<td headers="stat_0" class="gt_row gt_center">3,787 (2.6%)</td>
<td headers="stat_1" class="gt_row gt_center">3,787 (5.3%)</td>
<td headers="stat_2" class="gt_row gt_center">0 (0%)</td></tr>
  </tbody>
  
  <tfoot class="gt_footnotes">
    <tr>
      <td class="gt_footnote" colspan="4"><sup class="gt_footnote_marks">1</sup> Mean ± SD; n (%)</td>
    </tr>
  </tfoot>
</table>
</div>
</div>
</div>
</div>
<section id="initial-antihypertensive-use" class="level4">
<h4 class="anchored" data-anchor-id="initial-antihypertensive-use">Initial Antihypertensive Use</h4>
<p>In the overall population, most patients (75.4%) were initiated on a single agent, whereas 18.8% were initiated on 2 agents simultaneously, and 5.8% on ≥3 agents simultaneously. Crude rates of combination therapy were higher among Medicare- (28%) versus Medicaid-insured (21%) individuals, though these differences were minimized substantially after age-adjustment (<a href="initial_antihypertensive_prescribing_onefl_suppl.pdf" target="_blank">Table S3</a>).</p>
<p><a href="#fig-1">Figure&nbsp;1</a> summarizes the proportion of Medicaid-insured patients initiating each class of antihypertensives, as well as proportion initiating each drug within each class. Briefly, the most common classes initiated were ACEIs (39% of patients) and β-blockers (31%), followed by DHP CCBs (22%), thiazide diuretics (19%) and ARBs (11%). Use of most classes was predominated by a single agent, namely lisinopril (94% of ACEI initiators), amlodipine (87% of DHP CCB initiators), hydrochlorothiazide (94% of thiazide initiators), and losartan (88% of ARB initiators). β-blockers were more evenly distributed across metoprolol (47%), propranolol (17%), carvedilol (14%) and atenolol and labetalol (each 11%). <a href="#fig-2">Figure&nbsp;2</a> presents corresponding information for Medicare-insured patients, in which ACEIs (37%) and β-blockers (36%) were the most often initiated, followed by DHP CCBs (21%), thiazide diuretics (17%), and ARBs (13%). The rank-order of drugs within class was generally similar among the Medicare-, compared with Medicaid-insured, cohorts.</p>
<div id="fig-1" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<p></p><figcaption class="figure-caption">Figure&nbsp;1: Proportion of patients prescribed each antihypertensive class, among Medicaid-insured patients with newly-treated hypertension. Numbers to the right of bars represent distinct patients. Patients initiating multiple therapies are included in each category. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; DHP CCB, dihydropyridine calcium channel blocker; DRI, direct renin inhibitor (aliskiren)</figcaption><p></p>
<p><img src="initial_antihypertensive_prescribing_onefl_fig1.svg" class="img-fluid figure-img"></p>
</figure>
</div>
<div id="fig-2" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<p></p><figcaption class="figure-caption">Figure&nbsp;2: Proportion of patients prescribed each antihypertensive class, among Medicare-insured patients with newly-treated hypertension. Numbers to the right of bars represent distinct patients. Patients initiating multiple therapies are included in each category. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; DHP CCB, dihydropyridine calcium channel blocker; DRI, direct renin inhibitor (aliskiren).</figcaption><p></p>
<p><img src="initial_antihypertensive_prescribing_onefl_fig2.svg" class="img-fluid figure-img"></p>
</figure>
</div>
<p>Antihypertensive use patterns among patients initiating monotherapy within the Medicaid cohort were generally similar to the overall Medicaid cohort in terms of rank ordering of classes and drugs within class (<a href="initial_antihypertensive_prescribing_onefl_suppl.pdf" target="_blank">Figure S3</a>). Likewise, compared to the overall Medicare cohort, patients initiating monotherapy had similar antihypertensive initiation patterns except that ARBs were initiated more often than thiazide diuretics (10% vs.&nbsp;7% among monotherapy initiators; 13% vs.&nbsp;17% among all Medicare patients) (<a href="initial_antihypertensive_prescribing_onefl_suppl.pdf" target="_blank">Figure S4</a>). Among patients initiating two antihypertensives simultaneously, the most common combination was an ACEI + thiazide diuretic (24% of all 2-drug combinations overall), which was the preferred two-drug combination in both cohorts (31% of all 2-drug combinations in the Medicaid cohort and 18% in the Medicare cohort; <a href="initial_antihypertensive_prescribing_onefl_suppl.pdf" target="_blank">Table S4</a>). The next three most common combinations were ACEI + β-blocker (14% overall), ARB + thiazide diuretic (11% overall) and ACEI + CCB (10% overall). Among Medicaid recipients, only 59% of all two-drug combinations were considered guideline-concordant (i.e., using drugs from two first-line antihypertensives) per current U.S. guidelines, whereas 36% were partially concordant (combining one first-line and one second-line antihypertensive) and 5% were fully discordant (<a href="initial_antihypertensive_prescribing_onefl_suppl.pdf" target="_blank">Figure S5</a>). Among Medicare recipients, 47% of patients initiated guideline-concordant two-drug combinations, whereas 45% were partially concordant and 8% were fully discordant (<a href="initial_antihypertensive_prescribing_onefl_suppl.pdf" target="_blank">Figure S6</a>). Finally, among all patients initiating ≥2 antihypertensives concomitantly, nearly one-third (33.8%) used at least one fixed-dose combination product, with a slightly higher proportion among Medicaid vs.&nbsp;Medicare recipients (35.2% vs.&nbsp;32.7%).</p>
</section>
<section id="time-trends" class="level4">
<h4 class="anchored" data-anchor-id="time-trends">Time Trends</h4>
<p><a href="#fig-3">Figure&nbsp;3</a> and <a href="initial_antihypertensive_prescribing_onefl_suppl.pdf" target="_blank">Figure S7</a> summarize the proportion of patients starting each class over time. Notable changes from 2013 through 2021 were increased use of DHP CCBs (20% to 27% overall; p&lt;0.0001) and decreased use of β-blockers (32% to 26%; p&lt;0.0001) among Medicaid recipients. Dihydropyridine CCB initiation also increased over time in Medicare recipients (20% in 2013 to 24% in 2017), whereas but no change was observed for β-blockers. ACEI initiation decreased modestly overall (39% to 36%; p&lt;0.0001) and in each cohort separately, as did thiazide use (Medicaid, 26% to 16%, p&lt;0.0001; Medicare, 18% to 14%, p&lt;0.0001). ARB initiation increased by a similar magnitude (Medicaid, 3% to 13%, p&lt;0.0001; Medicare, 11% to 15%, p&lt;0.0001). Time trends of drug within class are presented in <a href="initial_antihypertensive_prescribing_onefl_suppl.pdf" target="_blank">Figure S8</a> and <a href="initial_antihypertensive_prescribing_onefl_suppl.pdf" target="_blank">S9</a>. Analyses limited to patients initiating monotherapy showed remarkably similar trends (data not shown).</p>
<div id="fig-3" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<p></p><figcaption class="figure-caption">Figure&nbsp;3: Time trends in initial use of antihypertensive classes, 2013-2021. Panel A represents Medicaid-insured individuals; Panel B represents Medicare-insured individuals. All trends for major classes of antihypertensives in each cohort were significant at p&lt;0.0001, excepting β-blockers in the Medicare cohort, p=0.48, using the Cochrane-Armitage test. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; DHP CCB, dihydropyridine calcium channel blocker; DRI, direct renin inhibitor (aliskiren).</figcaption><p></p>
<p><img src="initial_antihypertensive_prescribing_onefl_fig3.svg" class="img-fluid figure-img"></p>
</figure>
</div>
</section>
<section id="stratified-analyses-demographics-and-comorbidities" class="level4">
<h4 class="anchored" data-anchor-id="stratified-analyses-demographics-and-comorbidities">Stratified Analyses: Demographics and Comorbidities</h4>
<p>The proportions of patients initiating each of the 5 major classes across pre-specified strata are summarized in <a href="#fig-4">Figure&nbsp;4</a> (Medicaid) and <a href="#fig-5">Figure&nbsp;5</a> (Medicare), with additional detailed data in <a href="initial_antihypertensive_prescribing_onefl_suppl.pdf" target="_blank">Table S5</a>. Among both cohorts, men were more likely than women to initiate ACEIs, whereas the reverse was true for thiazides, especially among Medicaid recipients (Panel A). Black patients were more likely to initiate CCBs (primarily DHP CCBs) or thiazides, compared with White and Asian patients in both cohorts (Panel B). Black patients, compared with White and Asian patients, were also less likely to initiate ACEIs in the Medicaid cohort, whereas no meaningful difference was observed in Medicare-insured individuals. Additional analyses among monotherapy-treated Black participants with and without CKD or HF are summarized in <a href="initial_antihypertensive_prescribing_onefl_suppl.pdf" target="_blank">Figure S10</a>. Briefly, comparing those with either CKD or HF versus without CKD nor HF, we observed fewer patients initiating ACEIs (24% vs.&nbsp;27% [SMD, 0.08] in the Medicaid cohort; 20% vs.&nbsp;31% [SMD, 0.26] in the Medicare cohort) and thiazides (12% vs.&nbsp;18% [SMD, 0.16] in Medicaid; 6% vs.&nbsp;12% [SMD, 0.23] in Medicare), and similar proportions initiating ARBs. In the Medicare cohort, β-blocker use was much higher in the CKD/HF population (36%) compared to those with neither CKD nor HF (22%; SMD, 0.31), whereas we observed little difference in β-blocker use in these populations among Medicaid-insured (22% vs.&nbsp;18%; SMD, 0.08).</p>
<div id="fig-4" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<p></p><figcaption class="figure-caption">Figure&nbsp;4: Proportion of Medicaid-insured patients prescribed first-line antihypertensive classes, stratified by selected demographics and comorbidities. Data are presented by sex (panel A), race including only racial groups with sufficient representation (B), ethnicity (C), and presence/absence of type 2 diabetes (D), CKD (E), or clinical ASCVD (F). Legends for each panel correspond to darker or lighter shaded bars within each antihypertensive class. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; DHP CCB, dihydropyridine calcium channel blocker; T2DM, type 2 diabetes mellitus.</figcaption><p></p>
<p><img src="initial_antihypertensive_prescribing_onefl_fig4.svg" class="img-fluid figure-img"></p>
</figure>
</div>
<div id="fig-5" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<p></p><figcaption class="figure-caption">Figure&nbsp;5: Proportion of Medicare-insured patients prescribed first-line antihypertensive classes, stratified by selected demographics and comorbidities. Data are presented by sex (panel A), race including only racial groups with sufficient representation (B), ethnicity (C), and presence/absence of type 2 diabetes (D), CKD (E), or clinical ASCVD (F). Legends for each panel correspond to darker or lighter shaded bars within each antihypertensive class. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; DHP CCB, dihydropyridine calcium channel blocker; T2DM, type 2 diabetes mellitus.</figcaption><p></p>
<p><img src="initial_antihypertensive_prescribing_onefl_fig5.svg" class="img-fluid figure-img"></p>
</figure>
</div>
<p>Hispanic patients had moderately higher initiation of ACEI or ARB therapy and lower initiation of CCBs or β-blockers in each cohort (<a href="#fig-4">Figure&nbsp;4</a> &amp; <a href="#fig-5">Figure&nbsp;5</a>, Panel C). Diabetes, versus no diabetes, was associated with greater ACEI but not ARB use in both cohorts, as well as higher β-blocker use, but lower CCB and thiazide use (<a href="#fig-4">Figure&nbsp;4</a> &amp; <a href="#fig-5">Figure&nbsp;5</a>, Panel D). ACEIs were initiated in only 30% of patients meeting CKD criteria overall (Medicaid, 35%; Medicare, 28%), versus 40% of those not meeting CKD criteria (Medicaid, 42%; Medicare, 39%); CCB and β-blockers were each initiated considerably more commonly in those with CKD, whereas thiazides were initiated more commonly in those without CKD (<a href="#fig-4">Figure&nbsp;4</a> &amp; <a href="#fig-5">Figure&nbsp;5</a>, Panel E). Finally, among patients with ASCVD in both cohorts, approximately half initiated a β-blocker, whereas only 10% initiated a thiazide, and use of other classes differed only modestly (≤6%) between those with and without ASCVD (<a href="#fig-4">Figure&nbsp;4</a> &amp; <a href="#fig-5">Figure&nbsp;5</a>, Panel F).</p>
</section>
</section>
<section id="discussion" class="level3">
<h3 class="anchored" data-anchor-id="discussion">DISCUSSION</h3>
<p>In this large, population-based study, we characterized antihypertensive regimens among patients with newly-treated hypertension. We focused our cohort among Medicare and Medicaid recipients who initiated ≥1 first-line antihypertensive classes (including β-blockers, considered first-line therapy during a portion of our study years), to better understand treatment initiation patterns and to complement existing literature which provide data on prevalent hypertension cohorts. Our principal findings are that initiation of monotherapy remains remarkably common and significant variation exists in initial antihypertensive regimens, with ≤41% of patients prescribed any single class in either study population. Within classes, there exists very little variation in choice of initial antihypertensive drug, especially among current first-line therapies (ACEI, ARB, CCBs, thiazides), in which a single drug predominates in ≥70% of cases. Time trends in antihypertensive initiation have remained fairly stable, although ACEI and β-blocker use (among Medicaid recipients) has decreased significantly, replaced by increased DHP CCB and ARB use between 2013 and 2021. Finally, we observed notable differences in antihypertensive initiation in stratified analyses across demographic and clinical characteristics. To our knowledge, this is one of the largest and most detailed characterizations of real-world utilization of antihypertensives in newly-treated patients.</p>
<p>Limited data have been published regarding initial use of antihypertensive classes. A recent study examined time trends in first-line antihypertensives between 2008-2017 in Medicare recipients, primarily focused on patients initiating monotherapy.18 In that population, thiazide initiation decreased and CCB initiation increased, similar to our findings. In contrast, they found reduced initiation of β-blockers over time, whereas we observed stable β-blocker initiation, though β-blockers remain one of the most commonly initiated antihypertensives through 2017 in both studies. Finally, they observed increased use of ACEIs and ARBs, particularly among individuals without any comorbidities. It remains unclear to what extent this finding was driven by increased ACEI initiation, ARB initiation, or both. Among both our Medicare and Medicaid populations, we found consistent decreases in ACEI initiation over time, whereas ARB initiation increased in both cohorts.<span class="citation" data-cites="anderson_national_2022"><sup><a href="#ref-anderson_national_2022" role="doc-biblioref">18</a></sup></span> Thus, it is possible that these findings are consistent. On the other hand, our data suggest that comparatively few patients initiate ARBs compared with ACEIs, even in the most recent years. Few other studies have explicitly characterized antihypertensive new user regimens; however, some additional insights may be gleaned from “real-world” comparative effectiveness studies enrolling only new antihypertensive users. For example, the LEGEND-HTN study included only new antihypertensive users of first-line antihypertensives from multiple claims and EHR-based cohorts, and found, similar to our study, that ACEIs were the most common antihypertensive initiated across multiple claims and EHR-based cohorts, followed by DHP CCBs, thiazides, ARBs, and non-DHP CCBs (β-blockers were not studied).<span class="citation" data-cites="suchard_comprehensive_2019"><sup><a href="#ref-suchard_comprehensive_2019" role="doc-biblioref">19</a></sup></span></p>
<p>Compared to recent data from U.S. prevalent hypertension cohorts, our findings regarding initial antihypertensive classes share some similarities but also noteworthy differences. For example, a recent analysis of National Health and Nutrition Examination Survey (NHANES) data found that from 2013-2016, nearly three quarters (74%) of antihypertensive regimens contained an ACEI or ARB, whereas 43% contained a diuretic, 35% contained a β-blocker, and 29% contained a CCB.<span class="citation" data-cites="derington_trends_2020"><sup><a href="#ref-derington_trends_2020" role="doc-biblioref">14</a></sup></span> Our data, too, showed ACEIs as the predominant class initiated overall and in the Medicaid cohort for every year over the study period, and only used marginally less in the Medicare cohort. However, we observed considerably lower proportions of initial regimens containing CCBs (&lt;25%) and thiazides (&lt;20%), despite having a considerably higher proportion of Black patients and, as might be expected with a newly-diagnosed hypertensive population, fewer patients with diagnosed CKD or HF, than in the NHANES samples. Similar trends were observed among those initiating only monotherapy in our study. Our results also revealed remarkably low ARB initiation, though there was evidence of a moderate shift over time from ACEI to ARB as preferred renin angiotensin system inhibitor. This finding may reflect increasingly robust evidence for their equivalent outcomes in hypertension and greater tolerability with ARBs,<span class="citation" data-cites="chen_comparative_2021 bangalore_angiotensin-converting_2016"><sup><a href="#ref-chen_comparative_2021" role="doc-biblioref">20</a>,<a href="#ref-bangalore_angiotensin-converting_2016" role="doc-biblioref">21</a></sup></span> as well as a narrowing of practice differences between U.S. and international cohorts, the latter of which generally show considerably higher ARB initiation among new antihypertensive users.<span class="citation" data-cites="hou_frequency_2021 selmer_choice_2012 rea_adherence_2021"><sup><a href="#ref-hou_frequency_2021" role="doc-biblioref">4</a>,<a href="#ref-selmer_choice_2012" role="doc-biblioref">22</a>,<a href="#ref-rea_adherence_2021" role="doc-biblioref">23</a></sup></span> Finally, among Medicaid recipients, we observed reduced initiation of β-blockers and greater initiation of DHP CCBs, such that by 2021, DHP CCBs (and CCBs, overall) were initiated more frequently than β-blockers. Among Medicare patients, we saw a similar rise in DHP CCB use, but no change in β-blocker use. These findings are consistent with the evolving recognition of DHP CCB effectiveness as antihypertensives and concerns that β-blockers still have a role in patients with ASCVD, but may be less effective at reducing risk of major adverse outcomes in uncomplicated hypertension.<span class="citation" data-cites="chan_you_comprehensive_2021 jamerson_benazepril_2008 wiysonge_beta-blockers_2017"><sup><a href="#ref-chan_you_comprehensive_2021" role="doc-biblioref">24</a>–<a href="#ref-wiysonge_beta-blockers_2017" role="doc-biblioref">26</a></sup></span></p>
<p>Within antihypertensive classes, we saw remarkably little variation in prescribing. For all first-line classes except β-blockers, a single drug accounted for ≥70% of all initiations within class. Indeed, the four predominant drugs (lisinopril, amlodipine, hydrochlorothiazide, and losartan) accounted for &gt;60% of all antihypertensives initiated and at least one of these drugs was present in 70% of regimens. Analysis of trends over time revealed generally stable market for most first-line agents share during the study period, with one notable exception: losartan made up 64% of all ARB initiations in 2013, increasing to 91% in 2021. Increasing trends were observed in both the Medicare- and Medicaid-insured cohorts over time, though the latter tended to initiate losartan at an approximately 10% higher rate each year than the Medicare-insured cohort. This increasing use of losartan is somewhat surprising in light of the fact that losartan often requires twice or thrice-daily dosing and has lower persistence compared with other ARBs.<span class="citation" data-cites="hasford_population-based_2002"><sup><a href="#ref-hasford_population-based_2002" role="doc-biblioref">27</a></sup></span></p>
<p>Our overall findings must also be considered in the context of the populations in which they were observed. Specifically, our data also revealed several noteworthy differences in antihypertensive prescribing across demographic variables. Our overall cohort was comprised of ~57% women and we observed significantly greater initiation of ACEIs and less initiation of thiazides in this group compared with men. This finding is qualitatively consistent with prior research in prevalent hypertensive cohorts,13 though the magnitudes of difference observed in our population was markedly greater. Interestingly, in comparisons across races, we found that ACEIs were most commonly initiated across all races, followed by β-blockers (White and Asian patients) and CCBs (Black patients), particularly in the absence of ASCVD. The greater frequency of ACEI initiation observed in Black patients is only partially explained by their greater likelihood of receiving dual therapy compared with White patients (29% vs.&nbsp;25%). Even among Black patients receiving monotherapy, RAS inhibitors (including β-blockers) accounted for &gt;50% of initial regimens in both Medicaid- and Medicare-insured. Current guidelines recommend a CCB or thiazide diuretic in Black patients without compelling indications for specific antihypertensive classes,3 yet fewer than half of Black patients received such therapy (~45% of all Black patients and ~46% of those without CKD/HF who initiated monotherapy). And, we observed comparatively less initiation of ACEI/ARB therapy in Black individuals with diagnosed CKD or HF. Combined with recent findings regarding racial disparities in treatment intensification,<span class="citation" data-cites="fontil_association_2022"><sup><a href="#ref-fontil_association_2022" role="doc-biblioref">28</a></sup></span> our findings may help explain some of the well-known disparities in hypertension control comparing White and Black Americans.<span class="citation" data-cites="fontil_association_2022 aggarwal_racialethnic_2021"><sup><a href="#ref-fontil_association_2022" role="doc-biblioref">28</a>,<a href="#ref-aggarwal_racialethnic_2021" role="doc-biblioref">29</a></sup></span></p>
<p>Our study has several noteworthy limitations. First, our cohorts were derived from insurance claims in OneFlorida (Medicaid, Medicare), rather than EHR data. We chose this approach because insurance claims ensure more complete information capture (during continuous eligibility periods), whereas an EHR-based approach would have likely resulted in significant misclassification of prevalent treated hypertension as newly treated hypertension because we could not ensure a sustained period of no antihypertensive use prior to first observed prescription. This design choice has several important implications. First, our study describes only antihypertensives ultimately filled by patients. We presume that the conversion rate of prescriptions to medication fills was non-differential across first-line classes and thus prescribing patterns would reflect similar antihypertensive initiation patterns, but we cannot be certain. Second, although we followed well-established and robust methods for identifying a new-user cohort from claims data, we cannot be certain that all patients initiated therapy specifically for hypertension. Indeed, it is plausible that some patients, particularly those initiating combination regimens, may have had other indications in addition to hypertension that guided antihypertensive selection. Accordingly, the prevalences of partially concordant and fully discordant combination therapy observed may reflect, at least in part, patients with multiple comorbid conditions (hypertension and, e.g., heart failure, coronary disease, or chronic kidney disease) in which the comorbidities prompted use of ‘second-line’ therapy. Relatedly, we required all patients initiate ≥1 first-line antihypertensive, and this approach excluded a relatively small number of patients initiating second-line agents only (<a href="initial_antihypertensive_prescribing_onefl_suppl.pdf" target="_blank">Figure S1</a>). Such patients were presumed to be likelier to initiate ‘antihypertensives’ for indications other than hypertension, which we could not rule out. However, it is probable that we excluded some patients who initiated second-line therapy for hypertension. We suspect these cases are relatively infrequent, as guideline recommendations regarding which classes constitute first-line therapy (other than for β-blockers) have been generally stable for decades. Nevertheless, our analyses of second-line agents overall, and their combinations, should be considered in this context. Fourth, we had limited data on socioeconomic information for patients included in the study; consequently, we were not able to ascertain the extent to which differences in socioeconomic status may have influenced, e.g., racial differences, in medication initiation. Finally, our findings come from publicly-insured individuals and may have limited generalizability to commercially-insured or uninsured individuals.</p>
<p>In summary, we conducted a detailed characterization of antihypertensive initiation patterns in newly-treated patients with hypertension. Although ACEIs were most commonly initiated across almost all analyses, we observed substantial variation across first-line classes overall and within pre-specified demographic and comorbidity strata. We also observed some trends suggesting uptake of current clinical guideline recommendations, namely greater initiation of CCBs and less initiation of β-blockers. Nevertheless, we noted several findings largely inconsistent with current recommendations in the U.S., including infrequent initiation of multi-drug regimens, moderately frequent use of combination regimens that do not prioritize first-line classes, and suboptimal use of some classes in patients for whom they are explicitly prioritized. Additional research is needed to better understand why such initial treatment choices are made and whether intervening on these factors may improve outcomes in these patients.</p>
</section>




<div id="quarto-appendix" class="default"><section id="funding" class="level2 appendix"><h2 class="quarto-appendix-heading">Funding</h2><div class="quarto-appendix-contents">

<p>This work was funded by the National Heart, Lung, and Blood Institute, K01 HL138172 (Dr.&nbsp;Smith). Research reported in this publication was also supported in part by the UF Center for Drug Evaluation and Safety; in part by the OneFlorida Clinical Data Network, funded by the Patient-Centered Outcomes Research Institute numbers CDRN-1501-26692 and RI-CRN-2020-005; in part by the OneFlorida Cancer Control Alliance, funded by the Florida Department of Health’s James and Esther King Biomedical Research Program number 4KB16; and in part by the University of Florida Clinical and Translational Science Institute and its Clinical and Translational Science Award (CTSA) hub partner, Florida State University, which are supported in part by three CTSA Program grants awarded on August 15, 2015, and renewed for five years on July 2, 2019, by the National Center for Advancing Translational Sciences of the National Institutes of Health. The UF-FSU CTSA grant numbers are UL1TR001427, KL2TR001429 and TL1TR001428. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, Patient-Centered Outcomes Research Institute (PCORI) or its Board of Governors or Methodology, the OneFlorida Clinical Research Consortium, the UF-FSU Clinical and Translational Science Institute, or the Florida Department of Health.</p>
</div></section><section id="disclosures" class="level2 appendix"><h2 class="quarto-appendix-heading">Disclosures</h2><div class="quarto-appendix-contents">

<p>The authors have no conflicts of interest to disclose.</p>
</div></section><section id="supplement" class="level2 appendix"><h2 class="quarto-appendix-heading">Supplement</h2><div class="quarto-appendix-contents">

<p>The data supplement for this paper can be found <a href="initial_antihypertensive_prescribing_onefl_suppl.pdf">here</a>.</p>



</div></section><section class="quarto-appendix-contents" role="doc-bibliography"><h2 class="anchored quarto-appendix-heading">References</h2><div id="refs" class="references csl-bib-body" role="doc-bibliography">
<div id="ref-muntner_blood_2022" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">1. </div><div class="csl-right-inline">Muntner P, Miles MA, Jaeger BC, et al. Blood pressure control among <span>US</span> adults, 2009 to 2012 through 2017 to 2020. <em>Hypertension</em>. 2022;79(9):1971-1980. doi:<a href="https://doi.org/10.1161/HYPERTENSIONAHA.122.19222">10.1161/HYPERTENSIONAHA.122.19222</a></div>
</div>
<div id="ref-williams_2018_2018" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">2. </div><div class="csl-right-inline">Williams B, Mancia G, Spiering W, et al. 2018 <span>ESC</span>/<span>ESH</span> guidelines for the management of arterial hypertension. <em>Eur Heart J</em>. 2018;39(33):3021-3104. doi:<a href="https://doi.org/10.1093/eurheartj/ehy339">10.1093/eurheartj/ehy339</a></div>
</div>
<div id="ref-whelton_2017_2018" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">3. </div><div class="csl-right-inline">Whelton PK, Carey RM, Aronow WS, et al. 2017 <span>ACC</span>/<span>AHA</span>/<span>AAPA</span>/<span>ABC</span>/<span>ACPM</span>/<span>AGS</span>/<span>APhA</span>/<span>ASH</span>/<span>ASPC</span>/<span>NMA</span>/<span>PCNA</span> guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. <em>Hypertension</em>. 2018;71(6):e13-e115. doi:<a href="https://doi.org/10.1161/HYP.0000000000000065">10.1161/HYP.0000000000000065</a></div>
</div>
<div id="ref-hou_frequency_2021" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">4. </div><div class="csl-right-inline">Hou W, Li D, Shen S, Lin J, Lou A, Wen A. Frequency and patterns of prescribing antihypertensive agents in outpatient kidney transplant recipients among six cities in china from 2011 to 2018. <em>Clin Ther</em>. 2021;43(3):602-612. doi:<a href="https://doi.org/10.1016/j.clinthera.2021.01.013">10.1016/j.clinthera.2021.01.013</a></div>
</div>
<div id="ref-gu_age_2016" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">5. </div><div class="csl-right-inline">Gu A, Yue Y, Argulian E. Age differences in treatment and control of hypertension in <span>US</span> physician offices, 2003-2010: A serial cross-sectional study. <em>Am J Med</em>. 2016;129(1):50-58.e4. doi:<a href="https://doi.org/10.1016/j.amjmed.2015.07.031">10.1016/j.amjmed.2015.07.031</a></div>
</div>
<div id="ref-gu_patterns_2019" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">6. </div><div class="csl-right-inline">Gu A, Farzadeh SN, Chang YJ, Kwong A, Lam S. Patterns of antihypertensive drug utilization among <span>US</span> adults with diabetes and comorbid hypertension: The national health and nutrition examination survey 1999-2014. <em>Clin Med Insights Cardiol</em>. 2019;13:1179546819839418. doi:<a href="https://doi.org/10.1177/1179546819839418">10.1177/1179546819839418</a></div>
</div>
<div id="ref-gu_racial_2017" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">7. </div><div class="csl-right-inline">Gu A, Yue Y, Desai RP, Argulian E. Racial and ethnic differences in antihypertensive medication use and blood pressure control among <span>US</span> adults with hypertension: The national health and nutrition examination survey, 2003 to 2012. <em>Circ Cardiovasc Qual Outcomes</em>. 2017;10(1):e003166. doi:<a href="https://doi.org/10.1161/CIRCOUTCOMES.116.003166">10.1161/CIRCOUTCOMES.116.003166</a></div>
</div>
<div id="ref-shah_current_2017" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">8. </div><div class="csl-right-inline">Shah SJ, Stafford RS. Current trends of hypertension treatment in the united states. <em>Am J Hypertens</em>. 2017;30(10):1008-1014. doi:<a href="https://doi.org/10.1093/ajh/hpx085">10.1093/ajh/hpx085</a></div>
</div>
<div id="ref-zhou_national_2015" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">9. </div><div class="csl-right-inline">Zhou M, Daubresse M, Stafford RS, Alexander GC. National trends in the ambulatory treatment of hypertension in the united states, 1997-2012. <em><span>PLoS</span> One</em>. 2015;10(3):e0119292. doi:<a href="https://doi.org/10.1371/journal.pone.0119292">10.1371/journal.pone.0119292</a></div>
</div>
<div id="ref-koifman_trends_2014" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">10. </div><div class="csl-right-inline">Koifman E, Tanne D, Molshatzki N, Leibowitz A, Grossman E. Trends in antihypertensive treatment–lessons from the national acute stroke israeli (<span>NASIS</span>) registry. <em>Blood Press</em>. 2014;23(5):262-269. doi:<a href="https://doi.org/10.3109/08037051.2013.876771">10.3109/08037051.2013.876771</a></div>
</div>
<div id="ref-wang_hypertension_2014" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">11. </div><div class="csl-right-inline">Wang Z, Wang X, Chen Z, et al. Hypertension control in community health centers across china: Analysis of antihypertensive drug treatment patterns. <em>Am J Hypertens</em>. 2014;27(2):252-259. doi:<a href="https://doi.org/10.1093/ajh/hpt186">10.1093/ajh/hpt186</a></div>
</div>
<div id="ref-weir_how_2011" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">12. </div><div class="csl-right-inline">Weir MR, Zappe D, Orloski LA, Sowers JR. How early should blood pressure control be achieved for optimal cardiovascular outcomes? <em>J Hum Hypertens</em>. 2011;25(4):211-217. doi:<a href="https://doi.org/10.1038/jhh.2010.64">10.1038/jhh.2010.64</a></div>
</div>
<div id="ref-zheutlin_factors_2022" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">13. </div><div class="csl-right-inline">Zheutlin AR, Derington CG, King JB, et al. Factors associated with antihypertensive monotherapy among <span>US</span> adults with treated hypertension and uncontrolled blood pressure overall and by race/ethnicity, national health and nutrition examination survey 2013-2018. <em>Am Heart J</em>. 2022;248:150-159. doi:<a href="https://doi.org/10.1016/j.ahj.2021.10.184">10.1016/j.ahj.2021.10.184</a></div>
</div>
<div id="ref-derington_trends_2020" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">14. </div><div class="csl-right-inline">Derington CG, King JB, Herrick JS, et al. Trends in antihypertensive medication monotherapy and combination use among <span>US</span> adults, national health and nutrition examination survey 2005-2016. <em>Hypertension</em>. 2020;75(4):973-981. doi:<a href="https://doi.org/10.1161/HYPERTENSIONAHA.119.14360">10.1161/HYPERTENSIONAHA.119.14360</a></div>
</div>
<div id="ref-oconnor_benefits_2013" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">15. </div><div class="csl-right-inline">O’Connor PJ, Vazquez-Benitez G, Schmittdiel JA, et al. Benefits of early hypertension control on cardiovascular outcomes in patients with diabetes. <em>Diabetes Care</em>. 2013;36(2):322-327. doi:<a href="https://doi.org/10.2337/dc12-0284">10.2337/dc12-0284</a></div>
</div>
<div id="ref-austin_using_2009" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">16. </div><div class="csl-right-inline">Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. <em>Communications in Statistics - Simulation and Computation</em>. 2009;38(6):1228-1234. doi:<a href="https://doi.org/10.1080/03610910902859574">10.1080/03610910902859574</a></div>
</div>
<div id="ref-noauthor_2014_nodate" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">17. </div><div class="csl-right-inline">2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the eighth joint national committee (<span>JNC</span> 8) <span></span> chronic kidney disease <span></span> <span>JAMA</span> <span></span> <span>JAMA</span> network. Accessed November 29, 2022. <a href="https://jamanetwork.com/journals/jama/fullarticle/1791497">https://jamanetwork.com/journals/jama/fullarticle/1791497</a></div>
</div>
<div id="ref-anderson_national_2022" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">18. </div><div class="csl-right-inline">Anderson TS, Ayanian JZ, Zaslavsky AM, Souza J, Landon BE. National trends in antihypertensive treatment among older adults by race and presence of comorbidity, 2008 to 2017. <em>J Gen Intern Med</em>. Published online April 26, 2022. doi:<a href="https://doi.org/10.1007/s11606-022-07612-3">10.1007/s11606-022-07612-3</a></div>
</div>
<div id="ref-suchard_comprehensive_2019" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">19. </div><div class="csl-right-inline">Suchard MA, Schuemie MJ, Krumholz HM, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: A systematic, multinational, large-scale analysis. <em>Lancet</em>. 2019;394(10211):1816-1826. doi:<a href="https://doi.org/10.1016/S0140-6736(19)32317-7">10.1016/S0140-6736(19)32317-7</a></div>
</div>
<div id="ref-chen_comparative_2021" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">20. </div><div class="csl-right-inline">Chen R, Suchard MA, Krumholz HM, et al. Comparative first-line effectiveness and safety of <span>ACE</span> (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: A multinational cohort study. <em>Hypertension</em>. 2021;78(3):591-603. doi:<a href="https://doi.org/10.1161/HYPERTENSIONAHA.120.16667">10.1161/HYPERTENSIONAHA.120.16667</a></div>
</div>
<div id="ref-bangalore_angiotensin-converting_2016" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">21. </div><div class="csl-right-inline">Bangalore S, Fakheri R, Toklu B, Ogedegbe G, Weintraub H, Messerli FH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials. <em>Mayo Clin Proc</em>. 2016;91(1):51-60. doi:<a href="https://doi.org/10.1016/j.mayocp.2015.10.019">10.1016/j.mayocp.2015.10.019</a></div>
</div>
<div id="ref-selmer_choice_2012" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">22. </div><div class="csl-right-inline">Selmer R, Blix HS, Landmark K, Reikvam A. Choice of initial antihypertensive drugs and persistence of drug use–a 4-year follow-up of 78,453 incident users. <em>Eur J Clin Pharmacol</em>. 2012;68(10):1435-1442. doi:<a href="https://doi.org/10.1007/s00228-012-1261-2">10.1007/s00228-012-1261-2</a></div>
</div>
<div id="ref-rea_adherence_2021" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">23. </div><div class="csl-right-inline">Rea F, Savaré L, Franchi M, Corrao G, Mancia G. Adherence to treatment by initial antihypertensive mono and combination therapies. <em>Am J Hypertens</em>. 2021;34(10):1083-1091. doi:<a href="https://doi.org/10.1093/ajh/hpab083">10.1093/ajh/hpab083</a></div>
</div>
<div id="ref-chan_you_comprehensive_2021" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">24. </div><div class="csl-right-inline">Chan You S, Krumholz HM, Suchard MA, et al. Comprehensive comparative effectiveness and safety of first-line β-blocker monotherapy in hypertensive patients: A large-scale multicenter observational study. <em>Hypertension</em>. 2021;77(5):1528-1538. doi:<a href="https://doi.org/10.1161/HYPERTENSIONAHA.120.16402">10.1161/HYPERTENSIONAHA.120.16402</a></div>
</div>
<div id="ref-jamerson_benazepril_2008" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">25. </div><div class="csl-right-inline">Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. <em>N Engl J Med</em>. 2008;359(23):2417-2428. doi:<a href="https://doi.org/10.1056/NEJMoa0806182">10.1056/NEJMoa0806182</a></div>
</div>
<div id="ref-wiysonge_beta-blockers_2017" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">26. </div><div class="csl-right-inline">Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Beta-blockers for hypertension. <em>Cochrane Database Syst Rev</em>. 2017;1(1):CD002003. doi:<a href="https://doi.org/10.1002/14651858.CD002003.pub5">10.1002/14651858.CD002003.pub5</a></div>
</div>
<div id="ref-hasford_population-based_2002" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">27. </div><div class="csl-right-inline">Hasford J, Mimran A, Simons WR. A population-based european cohort study of persistence in newly diagnosed hypertensive patients. <em>J Hum Hypertens</em>. 2002;16(8):569-575. doi:<a href="https://doi.org/10.1038/sj.jhh.1001451">10.1038/sj.jhh.1001451</a></div>
</div>
<div id="ref-fontil_association_2022" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">28. </div><div class="csl-right-inline">Fontil V, Pacca L, Bellows BK, et al. Association of differences in treatment intensification, missed visits, and scheduled follow-up interval with racial or ethnic disparities in blood pressure control. <em><span>JAMA</span> Cardiol</em>. 2022;7(2):204-212. doi:<a href="https://doi.org/10.1001/jamacardio.2021.4996">10.1001/jamacardio.2021.4996</a></div>
</div>
<div id="ref-aggarwal_racialethnic_2021" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">29. </div><div class="csl-right-inline">Aggarwal R, Chiu N, Wadhera RK, et al. Racial/ethnic disparities in hypertension prevalence, awareness, treatment, and control in the united states, 2013 to 2018. <em>Hypertension</em>. 2021;78(6):1719-1726. doi:<a href="https://doi.org/10.1161/HYPERTENSIONAHA.121.17570">10.1161/HYPERTENSIONAHA.121.17570</a></div>
</div>
</div></section></div></main> <!-- /main -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    target: function(trigger) {
      return trigger.previousElementSibling;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn) {
    const config = {
      allowHTML: true,
      content: contentFn,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start'
    };
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
</div> <!-- /content -->



</body></html>